VYNE Therapeutics' Vitiligo Trial Fails, Shares Plummet 74%
VYNE Therapeutics announced its Phase 2b trial for Repibresib gel in non-segmental vitiligo missed primary and key secondary endpoints, leading to trial termination and a share slump.
/ 1 item